

22. A medicament containing a peptide according to claim 20, together with auxiliary agents.
23. The medicament according to claim 21, in a galenic formulation for oral, intravenous, intramuscular, intracutaneous, or intrathecal administration or as an aerosol for transpulmonary administration.
24. Use of the medicament according to claim 21 comprising administering the medicament to a person in need thereof for the treatment or prophylaxis of a degenerative or metabolic disease of the bones.
25. The use of claim 24, wherein the disease is osteoporosis, osteomalacia, or osteopenia.
26. Use of the medicament according to claim 23 for the treatment and prophylaxis of degenerative and metabolic diseases of the bones, such as osteoporosis, osteomalacia and osteopenia.
27. The use of claim 26, wherein the disease is osteoporosis, osteomalacia, or osteopenia.
28. A process for the preparation of the purified peptide according to claim 19 comprising

- isolating the peptide from a hemofiltrate using (i) cation-exchange extraction followed by (ii) elution of adsorbed substances to produce a first extract containing proteins, (iii) renewed cation-exchange chromatography of the first extract to produce a second extract containing proteins, and subjecting the second extract to multistage reverse-phase chromatography to produce the purified peptide protein; or
  - synthesizing the peptide by solid-phase or liquid-phase synthesis; or
  - recombinant, heterologous expression of DNA encoding the peptide.
29. A process for the preparation of the purified peptide according to claim 20 comprising:
- isolating the peptide from a hemofiltrate using (i) cation-exchange extraction followed by (ii) elution of adsorbed substances to produce a first extract containing proteins, (iii) renewed cation-exchange chromatography of the first extract to produce a second extract containing proteins, and subjecting the second extract to multistage reverse-phase chromatography to produce the purified peptide protein; or
  - synthesizing the peptide by solid-phase or liquid-phase synthesis; or
  - recombinant, heterologous expression of DNA encoding the peptide.

REMARKS

Claims 19-29, presented hereby, are pending.